<SEC-DOCUMENT>0001193125-22-301902.txt : 20221209
<SEC-HEADER>0001193125-22-301902.hdr.sgml : 20221209
<ACCEPTANCE-DATETIME>20221209172705
ACCESSION NUMBER:		0001193125-22-301902
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20221209
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221209
DATE AS OF CHANGE:		20221209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Erasca, Inc.
		CENTRAL INDEX KEY:			0001761918
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831217027
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40602
		FILM NUMBER:		221455715

	BUSINESS ADDRESS:	
		STREET 1:		10835 ROAD TO THE CURE, SUITE 140
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 465-6511

	MAIL ADDRESS:	
		STREET 1:		10835 ROAD TO THE CURE, SUITE 140
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d435484d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eras="http://erasca.com/20221209" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-12-09_to_2022-12-09">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-12-09_to_2022-12-09">0001761918</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="eras-20221209.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-12-09_to_2022-12-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001761918</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-09</xbrli:startDate> <xbrli:endDate>2022-12-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-12-09_to_2022-12-09">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt:datemonthdayyearen">December 9, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-12-09_to_2022-12-09">Erasca, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-12-09_to_2022-12-09">001-40602</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-12-09_to_2022-12-09">83-1217027</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-12-09_to_2022-12-09">3115 Merryfield Row</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-12-09_to_2022-12-09">Suite 300</ix:nonNumeric><br /><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-12-09_to_2022-12-09">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-12-09_to_2022-12-09">92121</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-12-09_to_2022-12-09">(858)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-12-09_to_2022-12-09">465-6511</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><span style="font-family:pmingliu"><span style="font-family:Times New Roman"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><span style="font-family:pmingliu"><span style="font-family:Times New Roman"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><span style="font-family:pmingliu"><span style="font-family:Times New Roman"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><span style="font-family:pmingliu"><span style="font-family:Times New Roman"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-09_to_2022-12-09">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-09_to_2022-12-09">ERAS</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:exchnameen">NASDAQ Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <span style="font-family:pmingliu"><span style="font-family:Times New Roman"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span><span style="font-family:Times New Roman"></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:pmingliu"><span style="font-family:Times New Roman"><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-12-09_to_2022-12-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span><span style="font-family:Times New Roman"></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;3.02 Unregistered Sales of Equity Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on December 9, 2022, Erasca, Inc. (the Company) entered into an exclusive license agreement (the License Agreement) with Novartis Pharma AG (Novartis). On December 9, 2022, in partial consideration of the rights granted under the License Agreement, the Company issued 12,307,692 shares of the Company&#8217;s common stock, par value $0.0001 per share (Common Stock) to Novartis, at an issuance price of $6.50 per share. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering. The Company relied upon this exemption from registration based in part on representations made by Novartis in a stock issuance agreement entered into between the Company and Novartis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Goldman Sachs&#160;&amp; Co. LLC, as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of 15,384,616 shares (the Shares) of the Company&#8217;s Common Stock. The price to the public in this offering is $6.50 per Share. The Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $6.175 per Share. The net proceeds to the Company from this offering are expected to be approximately $94.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on December&#160;13, 2022, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement <span style="white-space:nowrap">No.&#160;333-266802)</span> which became effective with the Securities and Exchange Commission (the SEC) on August&#160;18, 2022, and prospectus supplement and accompanying prospectus filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 to this report and is incorporated by reference herein. A copy of the opinion of Latham&#160;&amp; Watkins LLP relating to the legality of the issuance and sale of Common Stock in the offering is attached as Exhibit 5.1 to this report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 9, 2022, the Company issued a press release announcing the pricing of the offering. A copy of the press release is attached as Exhibit&#160;99.1 to this report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company&#8217;s current beliefs and expectations and include, but are not limited to: the Company&#8217;s expectations regarding the completion of the offering and the expected net proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in the Company&#8217;s business described in the Company&#8217;s prior filings with the SEC, including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d435484dex11.htm">Underwriting Agreement, dated December&#160;9, 2022, by and among Erasca, Inc. and J.P. Morgan Securities LLC and Goldman Sachs&#160;&amp; Co. LLC, as representatives of the several underwriters named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d435484dex51.htm">Opinion of Latham&#160;&amp; Watkins LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d435484dex51.htm">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d435484dex991.htm">Press Release dated December&#160;9, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Erasca, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: December&#160;9, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ebun Garner</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Ebun Garner, General Counsel</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d435484dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Erasca, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15,384,616 Shares
of Common Stock, par value $0.0001 per share </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;9, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;in Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Erasca, Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1
hereto (the &#147;Underwriters&#148;), for whom J.P. Morgan Securities LLC (&#147;JPM&#148;) and Goldman Sachs&nbsp;&amp; Co. LLC (&#147;GS&#148;) are acting as representatives (the &#147;Representatives&#148;), an aggregate of 15,384,616 shares of
common stock, par value $0.0001 per share (&#147;Common Stock&#148;), of the Company (the &#147;Shares&#148;). The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the
&#147;Stock&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the
Shares, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement</U>. The Company has prepared and filed with the Securities and
Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-266802),</FONT> including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the
information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration
Statement&#148;; and the related prospectus covering the Shares in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under
the Securities Act) is hereinafter referred to as the &#147;Base Prospectus.&#148; If applicable, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and, if applicable, any prospectus included in the
Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the Base Prospectus, as supplemented by the prospectus supplement, in the form first used (or made available upon
request of purchasers pursuant to Rule 173 under </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the
&#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this
&#147;Agreement&#148;) to the Registration Statement, the Base Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement, the date of the Base Prospectus or the date of the Prospectus, as the case may be, and any reference to &#147;amend&#148;,
&#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934,
as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given
to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had
prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): the Registration Statement (including the documents incorporated by reference in the Registration
Statement) and each &#147;free-writing prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 7:20 A.M., New York City time, on December&nbsp;9, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase of the Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to issue and sell the Shares to the several Underwriters as provided in this Agreement, and each
Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $6.175 (the &#147;Purchase
Price&#148;) from the Company the respective number of Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company understands that the Underwriters intend to make a public offering of the Shares, and initially to
offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by
the Company to the Representatives at the offices of Cooley LLP, counsel for the Underwriters, at 10265 Science Center Drive, San Diego, CA 92121, at 10:00 A.M., New York City time, on December&nbsp;13, 2022, or at such other time or place on the
same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing. The time and date of such payment for the Shares is referred to herein as the &#147;Closing Date&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the Shares to be purchased on the Closing Date shall be made against delivery to the Representatives
for the respective accounts of the several Underwriters of the Shares to be purchased on such date with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through the
facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company
acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in
connection with determining the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is
advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own
independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the
Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter
that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and
as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in
the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize,
approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or its agents and
representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the Securities
Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives, such approval not to be unreasonably
withheld, conditioned, or delayed. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to
the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and such Issuer Free Writing Prospectus did not, and as of the Closing Date will not, contain any
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no
representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Emerging Growth Company</I>. From the time of initial confidential submission of
the registration statement relating to the Company&#146;s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication undertaken in reliance on Section&nbsp;5(d) of the Securities Act) through
the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;Emerging Growth Company&#148;).
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on either Section&nbsp;5(d) of, or
Rule 163B under, the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials.
</I>The Company (i)&nbsp;has not engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Statement and Prospectus.</I> The Registration Statement has been declared effective by the
Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering
of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such
post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus complied with and will comply in all material respects with the
Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Incorporated Documents. </I>The documents
incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such
documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so
filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and
will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Financial Statements.</I> The financial statements (including the related notes thereto) of the Company and its
consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange
Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods
specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#147;GAAP&#148;) in the United States applied on a consistent basis throughout the periods covered
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereby, except in the case of unaudited interim financial statements, which are subject to normal yearend adjustments, the effect of which would not individually or in the aggregate, be
materially adverse, and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects
the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of
the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby; all disclosures included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been
any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration
Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on
any class of capital stock, or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of
operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is
material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its
subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or
from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Organization and Good Standing.</I> The Company and each of its subsidiaries have been duly organized and are
validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the
conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so
qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations
or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The Company does not own or control, directly or indirectly, any
corporation, association or other entity that singularly, or in the aggregate, is a significant subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Capitalization.</I> The Company has an authorized capitalization as set forth in the Registration Statement, the
Pricing Disclosure Package and the Prospectus; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not
subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the
Prospectus,<B> </B>there are no outstanding rights (including, without limitation, pre-</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
emptive rights that have not been duly waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity
interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or
exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the
Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security
interest, restriction on voting or transfer or any other claim of any third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock Options. </I>With
respect to the stock options (the &#147;Stock Options&#148;) granted pursuant to the stock-based compensation plans of the Company (the &#147;Company Stock Plans&#148;), except as would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect (i)&nbsp;each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) so qualifies, (ii)&nbsp;each
grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the
Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and, to the knowledge of the Company (other than with respect to due execution and delivery
by the Company) the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other
applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Global Select Market (&#147;Nasdaq Market&#148;) and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly
accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company. Each Company Stock Plan is accurately described in all material respects in the Registration Statement, the Pricing Disclosure Package
and the Prospectus. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public
announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and
to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and
validly taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered
by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly
authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration
Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<I>Listing</I>. The Shares have been approved for listing on the Nasdaq Market, subject to notice of issuance. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<I>Description of the Underwriting Agreement.</I> This Agreement
conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its
charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or
observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any applicable law or statute or any judgment, order, rule or regulation of any court or arbitrator or
governmental or regulatory authority having jurisdiction over the Company or its subsidiaries, as applicable, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Conflicts. </I>The execution,
delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions by the Company contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not
(i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or
encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party
or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority having jurisdiction over the Company, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in
the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Consents Required.</I> No consent, filing, approval,
authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale
of the Shares and the consummation by the Company of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or
qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;), the Nasdaq Market and under applicable state securities laws in connection with the purchase and distribution of the Shares by the
Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<I>Legal Proceedings.</I> There are no legal, governmental or regulatory investigations,
actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property of the Company or any
of its subsidiaries is or may reasonably be expected to be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; to the
knowledge of the Company, no such Actions that would reasonably be expected, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, to have a Material Adverse Effect are threatened or contemplated by any
governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or
contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as
exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;<I>Independent Accountants</I>. KPMG LLP, who has certified certain financial statements of the Company and its
subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States)
and as required by the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<I>Title to Real and Personal Property</I>. The Company and its
subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are necessary to the respective businesses of the Company and its subsidiaries, in each case
free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or
(ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;<I>Title to Intellectual Property</I>. The Company and its subsidiaries own, or possess valid and enforceable
licenses or other sufficient rights to practice under or to use, all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights,
Internet domain names, copyrights, works of authorship, proprietary information and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures) in each case, owned or otherwise controlled by the Company or its subsidiaries and used in their respective businesses as currently conducted and as proposed to be conducted as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus (collectively, &#147;Intellectual Property&#148;). To the Company&#146;s knowledge, the conduct of its and its subsidiaries&#146; respective businesses as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus (&#147;Disclosure Documents&#148;)) do not currently and will not upon commercialization infringe, or misappropriate or otherwise conflict with any valid intellectual property rights of a third party, except any
such infringement, misappropriation or other conflict that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the Company&#146;s knowledge, the Intellectual Property owned by the Company has not
been adjudged by a court of competent jurisdiction (excluding ordinary course patent prosecution activities) to be invalid or unenforceable, in whole or in part. Except as disclosed in the Disclosure Documents: (i)&nbsp;to the Company&#146;s
knowledge there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Disclosure Documents&#148; as owned
by or licensed to the Company or its subsidiaries; and (ii)&nbsp;to the Company&#146;s knowledge there is no infringement by third parties of any Intellectual Property except any such infringement that would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. Except as disclosed in the Disclosure Documents, the Company is not in receipt of any pending or threatened in writing action, suit, proceeding or claim by any third party: (A)&nbsp;challenging
the Company&#146;s rights in or to any Intellectual Property, except any such pending or threatened action, suit, proceeding or claim that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; or
(B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, except any such pending or threatened action, suit, proceeding or claim that would not reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect. Except as disclosed in the Disclosure Documents, the Company and its subsidiaries have complied with the material terms of each </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect, except any <FONT
STYLE="white-space:nowrap">non-compliance</FONT> that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the Company&#146;s knowledge, except as disclosed in the Disclosure Documents, there are
no material defects of form in the preparation or filing of any of the issued patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken commercially reasonable steps to obtain executed
nondisclosure, confidentiality agreements and invention assignment agreements with their employees, and except as disclosed in the Disclosure Documents, to the Company&#146;s knowledge no employee of the Company is in or has been in violation of any
term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure
agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to the Intellectual Property and such employee&#146;s employment with the Company, except any
<FONT STYLE="white-space:nowrap">non-compliance</FONT> by such employees would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the Company&#146;s knowledge, the duty of candor and disclosure as
required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied with; and in all foreign offices having similar
requirements during the prosecution of the United States and foreign patents and patent applications, as applicable, included in the Intellectual Property owned by the Company have been complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;<I>Trade </I>Secrets. To the Company&#146;s knowledge, the Company and its subsidiaries have taken commercially
reasonable actions to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including confidential source code, ideas, research and development information, <FONT
STYLE="white-space:nowrap">know-how,</FONT> formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and
information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and there has been no unauthorized use or disclosure of such material trade secrets or confidential business
information, except as any such unauthorized use or disclosure would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;<I>IT Assets, Data Privacy and Security</I>. Except as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, (i)&nbsp;the computers, websites, applications, databases, software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the
Company and its subsidiaries (excluding any public networks) (collectively, the &#147;IT Assets&#148;) are adequate for, and operate and perform for, the operation of the business of the Company and its subsidiaries as currently conducted, and
(ii)&nbsp;the IT Assets are free and clear of all viruses, vulnerabilities, bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, the Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their confidential information and the privacy, confidentiality,
integrity, continuous operation, redundancy and security of all IT Assets and data (including all Personal Data (defined below), sensitive, confidential, or regulated data (collectively, &#147;Confidential Data&#148;)) used in connection with their
businesses. There have been no breaches of, violations of, outages of, or unlawful or unauthorized uses of, or accesses to IT Assets and no unlawful or unauthorized uses of, destruction of, losses of, alterations of, or accesses to Confidential
Data, nor any such incidents under internal review or investigation, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect, the Company and its subsidiaries comply, and have complied, with (i)&nbsp;applicable laws, statutes, regulations, directives, and industry standards concerning the protection, collection, use,
disclosure, transfer, storage, disposal, privacy, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confidentiality, integrity and security of Confidential Data (including to the extent applicable, the Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) as amended by
the Health Information Technology for Economic and Clinical Health Act (the &#147;HITECH Act&#148;); the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679); and the California Consumer Privacy Act (&#147;CCPA&#148;)
(collectively, the &#147;Privacy Laws&#148;)), and (ii)&nbsp;all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, policies, procedures, and contractual obligations relating to the privacy
and security of IT Assets and Confidential Data and to the protection of such IT Assets and Confidential Data from unlawful or unauthorized use, destruction, loss, alteration, access, misappropriation or modification (collectively, the &#147;Data
Protection Requirements&#148;). To the extent required by the Privacy Laws, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries have made all required
disclosures to and obtained all necessary consents from individuals (including, without limitation, clinical trial participants, customers, users, and personnel) for the Company&#146;s and its subsidiaries&#146; collection, use, disclosure,
transfer, and other processing of Confidential Data, and complied with all such disclosures and consents. To the knowledge of the Company, none of such disclosures made or contained in any policies or notices have been inaccurate, misleading,
deceptive or in violation of any Privacy Laws or Data Protection Requirements, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Personal Data&#148; means (i)&nbsp;any information
which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; (iv) &#147;personal data&#148; as defined by GDPR; (v)
&#147;personal information&#148; as defined by CCPA; and (vi)&nbsp;any other information that constitutes &#147;personal data&#148;, &#147;personal information&#148;, &#147;personally identifiable information&#148;, &#147;nonpublic personal
information&#148;, &#147;customer proprietary network information&#148;, &#147;individually identifiable health information&#148;, &#147;protected health information&#148;, or similar information under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Complaints</I>. Since June&nbsp;1, 2018, the Company has not received written notice of any complaint or
audit, proceeding, investigation (formal or informal) demand or claim made against the Company or its subsidiaries, by any person, government entity, regulator, group or other party in respect of the collection, use, disclosure, transfer, or other
processing of Confidential Data by the Company or its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<I>FDA Compliance</I>. Since June&nbsp;1,
2018, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company: (A)&nbsp;is and has been in compliance with all applicable statutes, rules or regulations of the U.S. Food and Drug
Administration (&#147;FDA&#148;) and other comparable governmental entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage,
import, export or disposal of any product under development, manufactured or distributed by the Company (collectively, &#147;Applicable Laws&#148;); (B) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled
letter or other written correspondence or written notice from the FDA or any governmental entity alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits
and supplements or amendments thereto required by any such Applicable Laws (&#147;Authorizations&#148;); (C) possesses all Authorizations and such Authorizations are valid and in full force and effect and the Company is not in violation of any term
of any such Authorizations; (D)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any applicable governmental entity alleging that any
product, operation, or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any governmental entity is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding;
(E)&nbsp;has not received written notice that the FDA or any governmental entity has taken, is taking or to the knowledge of the Company, intends to take action to limit, suspend or revoke any Authorizations; and (F)&nbsp;has filed, obtained,
maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or
supplemented by a subsequent submission). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<I>Tests and Preclinical and Clinical Trials</I>. The studies,
tests and preclinical and clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with all Authorizations and Applicable Laws;
the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company&#146;s knowledge, accurate in all material respects; the Company is not
aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the
Prospectus when viewed in the context in which such results are described and the clinical state of development; and the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination
or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Health Care Laws</I>. The Company and its subsidiaries are, and since June&nbsp;1, 2018
have been, in compliance with all Health Care Laws, except where the failure to so comply would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#147;Health Care
Laws&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the U.S.
Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Statements Law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287 and 1347 and the health care fraud criminal provisions under
HIPAA, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &#167; 17921 et seq.), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT>
the exclusions law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and the laws governing U.S. government funded
or sponsored healthcare programs. Since June&nbsp;1, 2018, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, neither the Company nor any of its subsidiaries has received written notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority that any product, operation, or activity is in violation of any Health Care
Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. Neither the Company nor any of its subsidiaries is a party to any corporate
integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority or body. Additionally, since June&nbsp;1, 2018, neither the Company, any of its
subsidiaries nor to the Company&#146;s knowledge, any of their respective employees, officers, directors, independent contractors, affiliates or agents has been excluded, suspended or debarred from participation in any U.S. federal health care
program or human clinical research or is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or
any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of
the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<I>Investment Company Act</I>. The Company is not and, after
giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment
company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the
&#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<I>Taxes.</I> The Company and its subsidiaries have paid all federal,
state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof and there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its
subsidiaries or any of their respective properties or assets, in each case, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<I>Licenses and Permits.</I> The Company and its subsidiaries possess, and are in compliance with the terms of,
all licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or
regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus
(&#147;Licenses&#148;), except where failures to so possess or comply would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received written notice
of any revocation or suspension of any such License or has any reason to believe that any such License will not be renewed in the ordinary course, except where such revocation or suspension would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to the Licenses, and, to the Company&#146;s knowledge, no event has occurred which
allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder, except where such revocation, termination or impairment would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries have filed, obtained, maintained
or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required and that all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) as required for maintenance of their Licenses that are necessary for the conduct of their respective businesses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its
subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146; principal
suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining agreement to
which it is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Certain Environmental Matters. </I>(i)&nbsp;The Company and its subsidiaries
(x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable
requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y) have received
and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not received
notice of any actual </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or
release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated
with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and (iii)&nbsp;(x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other
than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental
Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;none of the
Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<I>Hazardous Materials</I>. There has been no storage, generation, transportation, use, handling, treatment,
Release or threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts or
omissions the Company or any of its subsidiaries is or could reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or any of its subsidiaries, or to the
knowledge of the Company, at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under any Environmental
Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Hazardous Materials&#148; means any material, chemical, substance, waste, pollutant,
contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally
occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. &#147;Release&#148; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging,
injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the
Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under common control with the
Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Code) would have any liability (each, a &#147;Plan&#148;)
has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of
Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the funding rules of
Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412
of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148; within the meaning
of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market value of the assets of each Plan exceeds the present value of all
benefits accrued under such Plan (determined based on those assumptions used to fund such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur;
(vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such
qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit
Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or
is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled
Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company and its subsidiaries&#146;
&#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company and its
subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<I>Disclosure Controls</I>. The Company and its subsidiaries maintain an effective system of &#147;disclosure
controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the applicable requirements of the Exchange Act and that has been designed to ensure that information
required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and
procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accounting Controls.</I> The Company and its subsidiaries maintain systems of &#147;internal control over
financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that have been designed to comply with the applicable requirements of the Exchange Act and have been designed by, or under the
supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in
accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material
respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. No material weaknesses in the Company&#146;s internal controls have been identified by the Company or its auditors (it being understood that
this subsection (mm)&nbsp;shall not require the Company to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;) as of an
earlier date than it would otherwise be required to so comply under applicable law). The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and
material weaknesses in the design or operation of internal controls over financial reporting known to the Company which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and
report financial information; and (ii)&nbsp;any fraud known to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<I>eXtensible Business Reporting Language</I>. The interactive data in eXtensible Business Reporting Language
included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<I>Insurance. </I>The Company and its subsidiaries have insurance covering their respective properties,
operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiaries and
their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to
continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary
to continue its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Unlawful Payments.</I> None of the Company, any of its subsidiaries, or any
director, officer, affiliate, or employee of the Company or any of its subsidiaries or, to the knowledge of the Company, any agent, representative, or other person associated with or acting on behalf of the Company or any of its subsidiaries or
affiliates has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken, or will take, an act in furtherance of an offer, payment, promise
or authorization or approval of any direct or indirect unlawful payment of money, property, gifts, any benefit, or anything of value to any foreign or domestic government or regulatory official, officer or employee, including of any government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or
is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions,
or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other
unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and each of its subsidiaries and affiliates have conducted their businesses in compliance
with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained
herein. Neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of
value, to any person in violation of any applicable anti-bribery or anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(qq)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with
Anti-Money Laundering Laws</I>. The operations of the Company and each of its subsidiaries are and have been conducted at all times in compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank
Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable money laundering statutes of all
jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency
(collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers or
employees, nor, to the knowledge of the Company, any agent, affiliate, representative, or other person associated with or acting on behalf of the Company or any of its subsidiaries is or is owned or controlled by one or more persons that are
currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and
including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority
(collectively, &#147;Sanctions&#148;), nor is the Company or any of its subsidiaries, directors, officers, or employees, or, to the knowledge of the Company, any agent,&nbsp;affiliate, representative, or other person associated with or acting on
behalf of the Company or any of its subsidiaries, or owned or controlled by one or more persons that are, located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran,
North Korea, Syria, the Crimea, Donetsk People&#146;s Republic, and Luhansk People&#146;s Republic regions of Ukraine, or any other Covered Region of Ukraine identified pursuant to Executive Order 14065 (each, a &#147;Sanctioned Country&#148;); and
the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund
or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or
(iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. The Company and its subsidiaries have not
knowingly engaged in, are not now knowingly engaged and will not knowingly engage in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ss)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited,
directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or similar ownership interest,
from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(tt)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract,
agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and
sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(uu)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Registration Rights</I>. No person has the right to require the Company or any of
its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares, except as described in each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus and except for such rights that have been&nbsp;duly&nbsp;satisfied&nbsp;or waived as of the date of this Agreement with respect to such filing or issuance and sale of Shares pursuant to
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vv)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization.</I> Neither the Company nor any of its subsidiaries or affiliates have
taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ww)&nbsp;&nbsp;&nbsp;&nbsp;<I>Margin Rules</I>. Neither the issuance, sale and delivery of
the Shares nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal
Reserve System or any other regulation of such Board of Governors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;<I>Forward-Looking Statements.</I> No
forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(yy)&nbsp;&nbsp;&nbsp;&nbsp;<I>Statistical and Market Data.</I> Nothing has come to the attention of the Company that has caused the Company
to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and
accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(zz)&nbsp;&nbsp;&nbsp;&nbsp;<I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of
the Company or to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act, including Section&nbsp;402 related to loans and Sections
302 and 906 related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;<I>Status under the Securities Act</I>. At the time of filing the
Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares
and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act
or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities
or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ccc)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Integration</I>. The Company has not sold, issued or distributed any securities during the <FONT
STYLE="white-space:nowrap">six-month</FONT> period preceding the date hereof, including any&nbsp;sales&nbsp;pursuant&nbsp;to&nbsp;Rule&nbsp;144A&nbsp;under, or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee
benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the time periods
specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; the Company will file promptly all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus
is required in connection with the offering or sale of the Shares; and the Company will use its reasonable best efforts to furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the
Underwriters in New York City prior to 10:00 A.M., New York City </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery of Copies.</I> The Company will deliver, upon written request, without charge, (i)&nbsp;to the
Representatives, two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each
Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including
all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such
period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the
Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments or
Supplements, Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the
Pricing Disclosure Package or the Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free
Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives
reasonably object. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice to the Representatives.</I> The Company will advise the Representatives promptly,
and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any
supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the
Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the
Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness
of the Registration Statement or preventing or suspending the use of any of the Pricing Disclosure Package, the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication or to the knowledge of the Company, the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus
Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package or any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus,
the Pricing Disclosure Package, or any such Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not misleading;
and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or to the knowledge of the Company, the initiation or threatening of any proceeding
for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any of the Pricing Disclosure Package or
the Prospectus or any Written </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Shares and, if any such order is
issued, will use reasonable best efforts to obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Ongoing
Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or
supplement the Prospectus to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as
the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or
supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will
comply with law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or
(ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission
(to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by
reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be
misleading or so that the Pricing Disclosure Package will comply with law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue Sky Compliance.</I> If
required by applicable law, the Company will use its reasonable best efforts to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will use its
reasonable best efforts to continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer
in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it
is not otherwise so subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Earnings Statement. </I>The Company will make generally available to its
security holders and the Representatives as soon as reasonably practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at
least twelve months beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; provided that the Company will be deemed to have furnished such
statement to its security holders and the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering Analysis and Retrieval system (&#147;EDGAR&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Clear Market.</I> For a period of 90 days after the date of the Prospectus (the &#147;Restricted Period&#148;),
the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise transfer or dispose of,
directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into or exercisable or exchangeable for Stock or (ii)&nbsp;enter into any swap, hedging or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of
the Stock or any such other securities, or publicly disclose the intention to undertake any of the foregoing in clause (i)&nbsp;or (ii), whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or
such other securities, in cash or otherwise, without the prior written consent of JPM and GS, other than the Shares to be sold hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described above do not apply to (i)&nbsp;the issuance of shares of Stock or securities convertible into or exercisable for
shares of Stock pursuant to the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (&#147;RSUs&#148;) (including net settlement), in each case outstanding on the date of this Agreement and described
in the Prospectus, provided each newly appointed director or executive officer that is a recipient of such securities during the Restricted Period enter into a lock up agreement with the Underwriters; (ii)&nbsp;grants of stock options, stock awards,
restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#146;s
employees, officers, directors, advisors, or consultants pursuant to the terms of a Company Stock Plan, in effect as of the Closing Date and described in the Prospectus, including the Company&#146;s 2021 Employee Stock Purchase Plan, provided that
each newly appointed director or executive officer that is a recipient of such shares of Stock or securities during the Restricted Period shall enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters
substantially in the form of Exhibit A hereto; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following the Closing
Date, in acquisitions or other similar strategic transactions, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters substantially in the form of Exhibit A hereto; (iv)&nbsp;the
filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement and described in the Prospectus or any assumed
benefit plan pursuant to an acquisition or similar strategic transaction; or (v)&nbsp;the shares of Stock to be issued pursuant to that certain Exclusive License Agreement by and between the Company and Novartis Pharma AG, dated on or about the date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Shares as
described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of proceeds&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly,
without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange Listing.</I> The Company will use its reasonable best efforts to list, subject to notice of issuance,
the Shares on the Nasdaq Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Reports.</I> For a period of three (3)&nbsp;years from the date of this
Agreement, so long as the Shares are outstanding, the Company will furnish to the Representatives, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of
any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to
the Representatives to the extent they are filed on EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Record Retention</I>. For a period of three
(3)&nbsp;years from the date of this Agreement, the Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under
the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>Shelf Renewal.</I> If immediately prior to the third
anniversary (the &#147;Renewal Deadline&#148;) of the initial effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and
is eligible to do so, a new automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representative. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the
Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared
effective within 180 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration statement relating to the
Shares. References herein to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<I>Emerging Growth Company</I>. The Company will promptly notify the Representatives if the Company ceases to be an
Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of Shares within the meaning of the Securities Act and (ii)&nbsp;completion of the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<I>Transfer Restrictions</I>. The Company will enforce the terms of all existing agreements, plans and arrangements
restricting the transfer by any holder of such holder&#146;s shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock (the &#147;Securities&#148;) following the offering of the Shares contemplated hereby.
The Company will issue stop-transfer instructions to the transfer agent with respect to any transaction that would constitute a breach of, or default under, such provisions. During the Restricted Period, the Company will enforce, and not waive or
amend, such stop-transfer instructions and any transfer restriction, including any &#147;market standoff,&#148; &#147;holdback&#148; or similar agreement or provision, applicable to any Securities unless the Company shall have obtained the prior
written consent of JPM and GS (such consent not to be unreasonably withheld, conditioned, or delayed); provided that this Section&nbsp;4(p) shall not prohibit the Company from effecting such a waiver or amendment to permit a transfer of securities
which is permissible under the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> letters described in Section&nbsp;6(l). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Agreements of the Underwriters</U>.&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter hereby represents and agrees
that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;It has not, and will not use, authorize use of, refer to or participate in the planning for use of, any
&#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and
any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by
reference) in a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(b) or Section&nbsp;4(c) above (including any electronic road show approved by the
Company in advance in writing), or (iii)&nbsp;any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an
&#147;Underwriter Free Writing Prospectus&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;It has not and will not, without the prior written consent
of the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided</I> that Underwriters may use a term
sheet substantially in the form of Annex B hereto without the consent of the Company; <I>provided further</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term
sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;It is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to
the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Shares on
the Closing Date as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement
shall be in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely
filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission
for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be
true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(h) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and
the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Officer&#146;s Certificate.</I> The Representatives shall have received on and as of the
Closing Date a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives (i)&nbsp;confirming that such officers have
carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(a) and 3(e) hereof are true and correct, (ii)&nbsp;confirming that
the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the
Closing Date, and (iii)&nbsp;to the effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Comfort
Letters</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;On the date of this Agreement and on the Closing Date, KPMG LLP shall have furnished to the
Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of
the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of the Registration Statement,
the Pricing Disclosure </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Package and the Prospectus; provided, that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than three business days
prior to such Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;On the date of this Agreement and on the Closing Date, the Company shall have
furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain financial data contained in the Pricing Disclosure Package and
the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Company.</I>
Latham&nbsp;&amp; Watkins LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date and
addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion of Intellectual Property Counsels for the Company</I>. Each of Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C. and Wilson&nbsp;Sonsini&nbsp;Goodrich&nbsp;&amp; Rosati, PC., intellectual property counsels for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date and
addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representatives shall have received on and as of the Closing Date, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Cooley LLP, counsel for the Underwriters, with respect to such matters as
the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation
or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Shares; and no injunction or order of any federal,
state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date satisfactory evidence
of the good standing of the Company in its jurisdiction of organization and its good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the
appropriate governmental authorities of such jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange Listing.</I> The Shares to be
delivered on the Closing Date shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and the officers, directors and certain stockholders of the Company, officers and directors of the Company
relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional Documents.</I> On or prior to the Closing Date, the Company shall have furnished to the
Representatives such further certificates and documents as the Representatives may reasonably request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and
liabilities (including, without limitation, reasonably incurred legal fees and other reasonably incurred expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or
several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement
thereto), any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with
any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of the
Company.</I> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are
based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being
understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the third
paragraph under the caption &#147;Underwriting&#148; and the information contained in the fifteenth paragraph under the caption &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory
investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall
promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under the preceding paragraphs </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>,
that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or
asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified
Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonably
incurred fees and expenses in such proceeding and shall pay the reasonably incurred fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person
has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in
addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the
same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such reasonably incurred fees and expenses shall be paid or reimbursed as they are incurred. Any such
separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who
signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if
settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall
have requested that an Indemnifying Person reimburse the Indemnified Person for reasonably incurred fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance
with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is
or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory
to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified
Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is
unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall
contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand,
and the Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred
to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the
one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and
commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the
Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if
contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include,
subject to the limitations set forth above, any reasonably incurred legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event
shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages
that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their
respective purchase obligations hereunder and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this
Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to
the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date: (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock
Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a
general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any
calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the
Closing Date, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Defaulting Underwriter</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If, on the Closing Date, any Underwriter defaults on its
obligation to purchase the Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons
satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such
Shares, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other
persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in
order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly
prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise
requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or
Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date does not exceed <FONT
STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the
number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting
Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any
arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of
Shares that remain unpurchased on the Closing Date exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph
(b)&nbsp;above, then this Agreement shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without
liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain
in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the
Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the
Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the
Shares and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the
Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in connection
with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum
(including the related fees and expenses of counsel for the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in
connection with any filing with, and clearance of the offering by, FINRA, provided, that the aggregate amount payable by the Company pursuant to clauses (iv)&nbsp;and (vii) shall not exceed $25,000; and (viii)&nbsp;all expenses incurred (provided,
however, that the Underwriters and the Company shall each pay 50% of the cost of chartering any aircraft to be used in connection with any &#147;road show&#148; by the Company and the Underwriters; and (ix)&nbsp;all expenses and application fees
related to the listing of the Shares on the Nasdaq Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If (i)&nbsp;this Agreement is terminated pursuant
to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to
reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in
connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to
purchase the Shares; provided, however that the Company shall still pay and reimburse any costs, fees or expenses of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters as provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon
the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or
shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely
by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers,
controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Defined Terms</U>. For
purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day
on which banks are permitted or required to be closed in New York City; (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act; and (d)&nbsp;the term &#147;significant subsidiary&#148; has the meaning
set forth in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of
Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which
information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been
duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT STYLE="white-space:nowrap">622-8358),</FONT> Attention: Equity Syndicate Desk; and c/o Goldman Sachs&nbsp;&amp; Co.
LLC, 200 West Street, New York, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-471-2526,</FONT></FONT></FONT>
or by email: <FONT STYLE="white-space:nowrap">Prospectus-ny@ny.email.gs.com.</FONT> Notices to the Company shall be given to it at Erasca, Inc., 10835 Road to the Cure, Suite 140 San Diego, CA 92121; Attention: General Counsel, with a copy, which
shall not constitute notice, to Latham&nbsp;&amp; Watkins LLP, 12670 High Bluff Drive, San Diego, CA 92130; Attention: Cheston J. Larson and Matthew T. Bush. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this
Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and
New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter
have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in
any court to the jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Waiver of Jury
Trial</I>. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special
Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if
this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under
the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As
used in this Section&nbsp;16(e): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 382.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any
standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered
by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments or
Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part
of, or to affect the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ERASCA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan E. Lim, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jonathan E. Lim, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chairman, Chief Executive Officer and Co-Founder</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GOLDMAN
SACHS&nbsp;&amp; CO. LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin H. Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name: Benjamin H. Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director, ECM Healthcare</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GOLDMAN SACHS&nbsp;&amp; CO. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name: Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,107,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,276,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,384,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Base Prospectus included in the Registration Statement </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Shares: 15,384,616 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Public Offering Price: $6.50 per Share </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Erasca, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term
Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re:&nbsp;&nbsp;&nbsp;&nbsp;Erasca, Inc. &#151; Public Offering </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as representatives (the &#147;Representatives&#148;) of the several Underwriters, propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with Erasca, Inc., a Delaware corporation (the
&#147;Company&#148;), providing for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock, par value $0.0001 per share (the
&#147;Common Stock&#148;), of the Company (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and
valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan Securities LLC and Goldman Sachs&nbsp;&amp; Co. LLC on behalf of the Underwriters, the undersigned
will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of business 90 days after the date of the final prospectus
supplement relating to the Public Offering (the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without
limitation, Common Stock or such other securities which may be deemed to be </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or
warrant) (collectively with the Common Stock, <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic
consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities, in cash or otherwise, (3)&nbsp;make any demand for or exercise any right with respect to the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or (4)&nbsp;publicly disclose the intention to do any of the
foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry
into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or
disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such
transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise. The undersigned further confirms that it has furnished the
Representatives with the details of any transaction the undersigned, or any of its affiliates, is a party to as of the date hereof, which transaction would have been restricted by this Letter Agreement if it had been entered into by the undersigned
during the Restricted Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;transfer the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the consent of the
Representatives: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, including without limitation to a charitable organization or educational institution,
or for bona fide estate planning purposes, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by will, other testamentary document or intestacy, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to any member of the undersigned&#146;s immediate family or to any trust for the direct or indirect benefit of the undersigned or the
immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any
relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) to a
partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i)&nbsp;through (iv)
above, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to
another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other
entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a
successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution to members or shareholders of the undersigned, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce
settlement, divorce decree or separation agreement, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) to the Company from an employee of the Company upon death, disability or
termination of employment, in each case, of such employee, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) as part of a sale of the undersigned&#146;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired in open market transactions after the closing date for the Public Offering, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to
purchase shares of Common Stock expiring during the Restricted Period (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result
of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter
Agreement, provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement
or plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus (including the documents incorporated by reference), and provided further that no public filing, report or announcement reporting a reduction
in beneficial ownership of shares of Common Stock shall be voluntarily made during the Restricted Period, and if the undersigned is required to file a report reporting a reduction in beneficial ownership of shares of Common Stock during the
Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause and that the shares of Common Stock received upon exercise of the stock option or warrant or
restricted stock unit or other right or vesting event are subject to this agreement, and no public filing, report or announcement shall be voluntarily made, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) transfers or dispositions of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to
the Company pursuant to any contractual arrangement in effect on the date of this agreement and disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus that provides for the repurchase of shares of Common Stock in
connection with the termination of the undersigned&#146;s employment with or service to the Company; provided, that no public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock shall be voluntarily
made during the Restricted Period, and if the undersigned is required to file a report reporting a reduction in beneficial ownership of shares of Common Stock during the Restricted Period, such report or filing shall clearly indicate in the
footnotes thereto that the filing relates to the circumstances described in this clause and no public filing, report or announcement shall be voluntarily made, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of
Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &#147;Change of Control&#148; shall mean the transfer (whether by tender
offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated
persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity)); <U>provided</U> that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the
undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this Letter Agreement, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) pursuant to a Trading Plan (as defined below) that is existing on the date hereof which has been provided to the Underwriters or its
legal counsel, provided that, to the extent a public announcement or filing under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), if any, is required </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by or on behalf of the undersigned or the Company regarding such transfer during the Restricted Period, such announcement or filing shall include the date that the trading plan was entered into
and a statement that such transfer is in accordance with an established Trading Plan, and provided further that the existing Trading Plan may not be amended during the Restricted Period to allow for an increase in the number of <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities that may be sold pursuant to such existing Trading Plan, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that (A)&nbsp;in the case
of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the
Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement, (B)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (ix), no filing by any
party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be made voluntarily in
connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above) and (C)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(vii), (viii) and
(xiii), it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a
reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto
the nature and conditions of such transfer, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) exercise outstanding options, settle restricted stock units or other equity awards or
exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any <FONT STYLE="white-space:nowrap">Lock-up</FONT> Securities received upon such exercise, vesting or
settlement shall be subject to the terms of this Letter Agreement, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) establish trading plans pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (each such plan, a &#147;Trading Plan&#148;); <U>provided</U> that (1)&nbsp;such Trading Plans
do not provide for the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the Restricted Period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement shall be required or made voluntarily
in connection with such Trading Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants that no single
natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act) beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the
undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the
securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. In the event that any signature is delivered by
facsimile transmission, electronic mail or otherwise by electronic transmission (including any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) evidencing an intent to sign this Letter Agreement,
such facsimile transmission, electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were an original. Execution and delivery of this Letter
Agreement by facsimile transmission, electronic mail or other electronic transmission is legal, valid and binding for all purposes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any
recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and
tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to the undersigned in
connection with the Public Offering, the Representatives and the other Underwriters are not making a recommendation to the undersigned to enter into this Letter Agreement and nothing set forth in such disclosures is intended to suggest that the
Representatives or any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that (i)&nbsp;if the Underwriting
Agreement does not become effective by January&nbsp;31, 2023, (ii) if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to
be sold thereunder, (iii)&nbsp;prior to payment for the Securities, the Registration Statement is withdrawn prior to the execution of the Underwriting Agreement or (iv)&nbsp;if the Company advises the Representatives in writing prior to the
execution of the Underwriting Agreement that it has determined not to proceed with the Public Offering, the undersigned shall be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are
entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature
page follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder <I>(Print exact name</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page to <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d435484dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12670 High Bluff Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1.858.523.5400 Fax:
+1.858.523.5450</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g435484dsp41.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Austin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Orange County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Century City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">December&nbsp;9, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tel Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Washington, D.C.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Erasca, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3115 Merryfield
Row, Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
<FONT STYLE="white-space:nowrap">(333-266802);</FONT> 15,384,616 shares of Common Stock, par value $0.0001 per share </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee
set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to Erasca, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in
connection with the offering of up to 15,384,616 shares of common stock of the Company, par value $0.0001 per share (the &#147;<B><I>Shares</I></B>&#148;). The offering of the Shares was made under<B><I> </I></B>a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on August&nbsp;11, 2022
(Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-266802)</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;), a base prospectus dated August&nbsp;18, 2022 included in the Registration Statement at the time it originally became
effective (the &#147;<B><I>Base Prospectus</I></B>&#148;), and a prospectus supplement dated December&nbsp;9, 2022 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the
&#147;<B><I>Prospectus</I></B>&#148;). The Shares are being sold pursuant to an underwriting agreement dated December&nbsp;9, 2022 by and among the Company and J.P. Morgan Securities LLC and Goldman Sachs&nbsp;&amp; Co. LLC, as representatives of
the several underwriters listed on Schedule 1 thereto (the &#147;<B><I>Underwriting Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This opinion is being
furnished in connection with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement,
the Base Prospectus or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As such counsel, we
have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual
matters without having independently verified such factual matters. We are opining herein as to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 9, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g435484dsp42.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have
been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by
the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we
have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated December&nbsp;9, 2022 and to the reference to our firm in the
Prospectus under the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission
thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d435484dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g435484g1209112804335.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Erasca Announces Pricing of Underwritten Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO,
December</B><B></B><B>&nbsp;9, 2022</B> <B>(GLOBE NEWSWIRE)</B> &#150; Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK
pathway-driven cancers, today announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to
Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $100&nbsp;million. The offering is expected to close on December&nbsp;13, 2022, subject to the
satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Erasca intends to use the net proceeds from this offering, together with its existing cash, cash
equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan and Goldman Sachs&nbsp;&amp; Co. LLC are acting as joint book-running managers for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT>
including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on August&nbsp;18, 2022. A prospectus supplement and accompanying prospectus relating to this offering will be filed
with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New
York 11717, by telephone at (866) <FONT STYLE="white-space:nowrap">803-9204,</FONT> or by email at <FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com,</FONT> or from Goldman Sachs&nbsp;&amp; Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, by telephone at (866) <FONT STYLE="white-space:nowrap">471-2526,</FONT> or by email at <FONT STYLE="white-space:nowrap">prospectus-ny@ny.email.gs.com.</FONT> Electronic copies of the prospectus supplement and
accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Erasca </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Erasca, our name is our mission: To <U>eras</U>e <U>ca</U>ncer. We are a clinical-stage precision oncology company singularly focused on discovering,
developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was <FONT STYLE="white-space:nowrap">co-founded</FONT> by leading pioneers in precision oncology and RAS targeting to create novel therapies and
combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team&#146;s
capabilities and experience, further guided by our scientific advisory board which includes the world&#146;s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Erasca cautions you that
statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beliefs and expectations and include, but are not limited to: our expectations regarding the satisfaction of customary closing conditions, the expected closing of the offering and the anticipated
use of proceeds therefrom. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as
well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading &#147;Risk Factors&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joyce
Allaire </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jallaire@lifesciadvisors.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Erasca, Inc. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>eras-20221209.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/10/2022 3:23:22 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:eras="http://erasca.com/20221209"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://erasca.com/20221209"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eras-20221209_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eras-20221209_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>eras-20221209_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/10/2022 3:23:22 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>eras-20221209_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/10/2022 3:23:22 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eras-20221209.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g435484dsp41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g435484dsp41.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"/VC_ &@W4WQ!^ =MX?U#4=,%E=BYET#XKV#ZUJ-KJMO%"9_LZZW<6EE)$R
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&RQL&Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g435484dsp42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g435484dsp42.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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0$BB2-5544 *%   % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g435484g1209112804335.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g435484g1209112804335.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 60# 2(  A$! Q$!_\0
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MNF6B6EE L%NF=L:=!GFH]3TBPUFW6#4;6.YB5MX5QP#ZU=HJ;N]RK*UCG?\
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@&0 /Y>?FQTK2HHI-MZL:26B"BBBD,**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139909365657088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001761918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  09,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Erasca, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1217027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3115 Merryfield Row<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">465-6511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERAS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d435484d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eras-20221209.xsd" xlink:type="simple"/>
    <context id="duration_2022-12-09_to_2022-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761918</identifier>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-12-09_to_2022-12-09">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-12-09_to_2022-12-09"
      id="Hidden_dei_EntityCentralIndexKey">0001761918</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-12-09_to_2022-12-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-12-09_to_2022-12-09">2022-12-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-12-09_to_2022-12-09">Erasca, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-12-09_to_2022-12-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-12-09_to_2022-12-09">001-40602</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-12-09_to_2022-12-09">83-1217027</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-12-09_to_2022-12-09">3115 Merryfield Row</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-12-09_to_2022-12-09">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-12-09_to_2022-12-09">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-12-09_to_2022-12-09">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-12-09_to_2022-12-09">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-12-09_to_2022-12-09">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-12-09_to_2022-12-09">465-6511</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-12-09_to_2022-12-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-12-09_to_2022-12-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-12-09_to_2022-12-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-12-09_to_2022-12-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-12-09_to_2022-12-09">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-09_to_2022-12-09">ERAS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-09_to_2022-12-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-12-09_to_2022-12-09">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-12-09_to_2022-12-09">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[@:XOE;*?C3<>W_YV6;R+U!+ P04    " !;BXE5GZ ;\+$"  #B#   #0
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !;BXE5!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %N+
MB55YT*$&[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( %N+B5697)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 6XN)56(TAMEU
M!   PA$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( %N+B56?H!OPL0(  .(,   -              "
M ;@,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 6XN)59>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  !@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d435484d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d435484d8k.htm">d435484d8k.htm</File>
    <File>d435484dex11.htm</File>
    <File>d435484dex51.htm</File>
    <File>d435484dex991.htm</File>
    <File>eras-20221209.xsd</File>
    <File>eras-20221209_lab.xml</File>
    <File>eras-20221209_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d435484d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d435484d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eras-20221209_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eras-20221209_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eras-20221209.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "eras",
   "nsuri": "http://erasca.com/20221209",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d435484d8k.htm",
      "contextRef": "duration_2022-12-09_to_2022-12-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d435484d8k.htm",
      "contextRef": "duration_2022-12-09_to_2022-12-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://erasca.com//20221209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-22-301902-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-301902-xbrl.zip
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MZ4="?U4*U#'L5JNW [OC9DPM7O*5._A@Q)D@B@2V5KV[%W_D%VRY,5*]MO\
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MGGDJN8,_"2&9NRO\/:WJWWQ5OPA[]E]02P,$%     @ 6XN)58FU0>-CHP
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MQ=5-UD#[Q3RK%G64-; #9_I=9LUY0-*!0H8O3=.JP%/!SRQ7U?0\J84?_,&
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MU,*R[#82NN<Q^F#[D1@\0CE-V&?LRP8U\83-Y#QMEZ-P42-C<+7K.;1G7L3
MI$R ^6 A3KS(B5+-/1,:@:G1+CV0P\SZ_?]B@J7$<:JJY-"EA5T2UCBQG87X
M[7CPX O*2@=]7D7->7*:-K.AZCW(BK3+96<K)&L092[LI%B6^WNAB#QDWL"L
MA@G\<JC-8:3QA1YP>N_0TP6_0HY+WL#&.+&'8!)J1:H)I/I6;'XT/E'+>/M
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MYQ)3^I$D6GG)<0XR-0>'%//!TL?CUO&;)*"S)TL=AUFK+R_5_;#*K.(0B^3
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MGS':62I*OS4F70,F[3'I_5/2%Z2KOKR?L[^GP0Q9CJX.E%X0KC6(_IH%DT$
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M\(*?GBP0ZTR6EI S9>%+=K$AO*$VH&E(; 9CK_ C9MV5>8;%H;DAN)P>U@I
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MTSK-W73/0*=8'=L96/E>[?_ QL$.6($D585%<]?;>*7NCSCX U_.P9V'=RV
M8CNNTZ/9R?-I;51*]BRW4&08/EK=0F!OU $]]42-Q8KO/5''&XA2Y>LOW,VS
MD*%-# =#_USQ^"1M..0?J.&=_LFAA\S-R)-HX683EPM_I8O(?,M+#RI.T)TH
MP8S$_3'ELR$K%+S?H=WS&BCOKFPA<4D)^ U(P4F*29/:XPNWHH%D>HMAYY8?
M\CY+_%'NL>(8J\,H"67.=G^O]W 'CG%.;'21 6D%E9H+@D00&" 9IJAWGNJ-
MIW+?_JY3J2[>;)AV/N_V,G+C?NQ3Z^ 0:,Q)S))*"V^!*6?C42$"J.F_^ &K
MAO'F>BE%W;>80]&HKC/0!724^#5.D5W*P1_PR0E0"\BR%)LRJK( R;Y(LOR0
M3")&BQFA<,X"46K0$;G%UZ#OAUP[RJ<^K<0V _41MI@H0&'0%Q .;DL4#'-[
M&],RWE(>K>GW:$AN! _>^($/*4'UW(&5W/D3<X*U!.<T1O?4P4<KC$C/.?:G
ML=WAF0BB!4&5EBJQ)(QOKJ[X?.!U0]?6^7BO; ZYG3,2TS1;NAXO+'IDV]94
MRNJ:6J;!8+*I5;.Q<8LSQM4/H0AMATMW:E@<'-^\%0HQ$X:),F^:5G"82CB]
MS170=8\A.*VQ_ES?ERM *Q6//*JUYY.B"LJDZ*RZR5C#%X6A!X$M*3L/6]4.
MBL/9[=MRM.[KYOB5 !9#AMV8\*:[P;":_XJTPQJ@'=-9/=>*/4&Z;D>J@ZC9
MCP-5.3PF*: /&=5BL$_<A/L9_"LOEZY,4XS[MR8LUO;#J%U12@7A<5Y'MX7I
MQEO56]QL.MSN7;/C5CBXA$#Z80T1%5A*'0NM%;M'5JDIM*)@HZL-P1GIE*M
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M%;J:(6J-QX9UDV.2R)?CX&0X$.38"G69YA<$:]N<8YX/[K!PD"6-*]61.=-
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M< RDW]MD+<TDS66:!L.IZ?>_EQ>(&E-';^'-BR0Z?1G3*2G<$]A%*X_LPK/
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MT>\][43CZAU^R'PBL[SRMDU5K&>:=@/__MX-6 2W04NC4')O_$1!G*>>8['
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M$@WLMF]@/F>P5E_EU ,F%G[!HD,&@/NX.]8=4IG2RM;'/C6..:"(^\BH'"5
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MN+)$C]H"W3<)VD=TK5?_4(1J2,^3?-[7'/DSFQ(EVA!N@"DX6/@28H5Y=D8
MG\ERF2:59"VH]I)!&[TD\&;<-.$)6"WD /BR&+ING$9OE:1&=[-Y X>-0VAW
M>L>1O.2KZ^ZAL#]N_:W#3778F&W7-+:.:8MFAU.6.-+E AF(^TP/1=)R&\J"
M E :W)J0@&&'25S=P+UG_<12D66XZ:()5;$,LJWY@>U1(4O,P''SM*\PU^J_
M0#D]5#0L?K6! W/*GY&P:O68!& )2R"[C=/R&-T4*-B%\M[8^GM>NR:9%[S7
MR^^1,:3S),M1H@CNMJRKYZD&)PIU4'I!HT(E[+)VNE$2T? G7#(707J.Z#WH
M;R'G*U4%]].GNDIMR&B^$U05I!W4TR.8V_0O8-PIXNE8;P'.;YYF#1(')5(E
MN87Y:G3Q:@&*HS#3H;,0A)Y8?K:H+L9?.&0-^%E (FZ&#F7F1I=/[<!"+&#>
M0*[]YW[D)60(?M CS<#SZXJSOH5Q2M[FA>AL,K'?^TZGT;3:^/$YR&L.XV^H
M2>M9V@'Y$GH5\1C BOGV_MY;\2DFJ7MYZR5FL8<,YBVFY=!2%!R0KK'F(<BY
M(@>%8K33H2N7Z.5AWY&% ]NU(L("7#BMM4S64F2H!XKZ3L*]W>CLCL^*1AZE
MQ0[^2KD)4TU^_PH*%^N3@&Z+/KH5P[I[VH88:7$4[J%K(HHB?_.R0"^?UL'>
M%G'XQB4[5I&[D ^ZS_6L1C"*@ME[?5>HUMSXAA8K+#S-UR[,42H]@\=2K>T0
MMX$7[>^AB$5A)NUU&4\J=5W^A$;KC^O*#-@9B36^,_-\-*2Y 4F)OE(P8<EE
MJ%1OSY96IQ?1<>?4$B2"EWJ&J!PVTS&7( WJ-'S P)'Q8",[*BHJ$DQJ$K1?
M&HX)'[8X,T3836;^>X<.CQF4[/D@<X]0!OL9MC,329&>IFM3J#4*2^AE,KXJ
M)61MG=)LE<K<F14;Q<N21B/@B6<*M(,5T!6C3?@I3 O@4L+.V1"-&U67\5"Z
M*4POJ=SPOZW5VZ%-VF*J&,=;D<H5K-Q!/O?M0021CFAR>"38#TM ()9T. HS
M)6 9.M!#>C9NHWM),CF$*1,^(2#GVTA,CYV29)+2R!83T! <?33)<165IT*&
MF#VS.YB+3]].JD9;YE05]*(J<W$)O'"TCK9)^XLVFK6B-'UA7GV##+EL+WR7
MZ"%L?*OPX<"&NL4NF_:BH5-*<X];@R$ETBN"J:8M4N?R(I'2:+G@7EOX>JR\
MLCG>-T_*)::Q\+S#AE9?,IXA=KJ2IC=[C9%(&W9<<R]F4K,<DNO4+1Y%X+WC
M\ESIIACQ,E@8%XNU)AS.-=#H_::G.*VB/*@X2"6-^8+=K^.>(7$Z+_OSXKT"
M0V5I&]A?,26<0;[)TKTB6?C!83UT@4?H3([6/:"8)B^1Z+FQG9'W@A$*5/6[
M;)32^W:@MZQE^"&H_&8'26[/2;6!BPE0D7CCX7N#^C5MC>RAO^'EA Y"#_QU
M_])B-Z.U_]X$]"I$NS*WV1<:&K!KL<"*8&16E%IQA;2DZ@4/J.5-M#\KT1F/
M?:!.<=_&++JFV=G!)[E=!R5,'JG#8$AR!^ [;!;OV'H$;G@Y_"B635A%X^10
M64AZQ%N$9!]()3$W@[CUM9R;@[7L<%:F 9ZO5H&K'JD%XIGR #.7,)E'!$X?
M1]-5OG0KPJE2)H: ^>L)_3H(+;?N7MW1KPUCQE:GN?"K275Y?];AE98ZXMX
M9'BDW(D?_8[AN, L'XB)$ +_B@K"2:H%G+1#HLP"^;KT,ORC")6AE1C,/$P[
M7LQ3;4&ZHJ)T^Z4AU[!Q?!BK-IOJN3I_)%D@_H*S ,'EYAF%@XR+9)GH3$>E
M\"V/PJD,X_;C1#AIP,KJ]C <.+N<4I,4!<C)GHMDH&SMVT8F+=!4*9E&2_L<
ML6^PTH"%?X"JJQ_#@XK]R+6!N15!79.,9,$43)L2)VL!:S;;93;GX0"BQ,U
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M+?IBJU>VX'BV=%N"LUFI4#?'$ILVQ]%QD92=)(8[O-.*8:U@CT&\$LMT,BE
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M]D2= &2"Z/;2IQF/-'P"3@3\N^U',#.%D.WC"$"I7NL+/-3_F^/_4$L#!!0
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MU]A@'U9>'[$O]M%;;/D74$L! A0#%     @ 6XN)59C=JA*I%   <'D   X
M             ( !     &0T,S4T.#1D.&LN:'1M4$L! A0#%     @ 6XN)
M58FU0>-CHP  [2D# !               ( !U10  &0T,S4T.#1D97@Q,2YH
M=&U02P$"% ,4    " !;BXE5H\%Q*@L+  #4,0  $               @ %F
MN   9#0S-30X-&1E>#4Q+FAT;5!+ 0(4 Q0    ( %N+B55EYCO]H@H  .<=
M   1              "  9_#  !D-#,U-#@T9&5X.3DQ+FAT;5!+ 0(4 Q0
M   ( %N+B57UQ1BN-@,  #L+   1              "  7#.  !E<F%S+3(P
M,C(Q,C Y+GAS9%!+ 0(4 Q0    ( %N+B56@%$FXIP8  *5)   5
M      "  =71  !E<F%S+3(P,C(Q,C Y7VQA8BYX;6Q02P$"% ,4    " !;
MBXE546V50-8$  #T+0  %0              @ &OV   97)A<RTR,#(R,3(P
?.5]P<F4N>&UL4$L%!@     '  < O $  +C=      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
